Incyte announces REACH2 pivotal trial of Ruxolitinib (Jakafi®) meets primary endpoint
Incyte announced positive results from the Novartis-sponsored pivotal Phase 3 REACH2 study evaluating ruxolitinib (Jakafi®) in patients with steroid-refractory acute graft-versus-host disease. The study met its primary endpoint of improving overall response rate at Day 28 with ruxolitinib. October 16, 2019